Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7428731
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RO7428731 is a bispecific T-cell engager (BiTE) antibody designed for immunotherapy in cancer, specifically targeting glioblastoma. It binds both the mutant epidermal growth factor receptor variant III (EGFRvIII), which is present on certain glioblastoma cells, and CD3 on T cells. By bringing T cells into close proximity with EGFRvIII-expressing tumor cells, it activates the immune system to attack and kill these cancerous cells. The drug is being developed by Roche/Hoffmann-La Roche and has been evaluated in phase 1 clinical trials for patients with newly diagnosed or recurrent EGFRvIII-positive glioblastoma[2][5][6][7].
- Other names
- anti-EGFRvIII/CD3 bispecific antibody RO7428731
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on RO7428731.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7428731.